Home
BCRX
BCRX News

Latest BioCryst Pharmaceuticals Inc. (BCRX) News on January 19, 2025

BioCryst price target raised to $12 from $10 at Evercore ISI

TipRanks

5 days ago

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.

9 days ago

Exploring High Growth Tech Stocks In January 2025

MT Newswires

9 days ago

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire

9 days ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

12 days ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

13 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Simply Wall St.

23 days ago

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In December 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

Simply Wall St.

2 months ago

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

MT Newswires

2 months ago

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

GlobeNewswire

2 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

2 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Strong Q3 2024 Revenue Growth

TipRanks

2 months ago

BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 months ago

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Thomson Reuters StreetEvents

2 months ago

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

GuruFocus.com

2 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

Motley Fool

2 months ago

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

2 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

2 months ago

BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued

Associated Press Finance

2 months ago

BioCryst: Q3 Earnings Snapshot

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

GlobeNewswire

3 months ago

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

Zacks

3 months ago

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

High Growth Tech Stocks To Watch In October 2024

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In October 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4

GlobeNewswire

3 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings

GuruFocus.com

3 months ago

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings

MT Newswires

3 months ago

BioCryst Pharmaceuticals' Study of Orladeyo Finds Hospitalization Reduction for Hereditary Angioedema Patients

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

GlobeNewswire

3 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?

Insider Monkey

3 months ago

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

GlobeNewswire

3 months ago

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2

Insider Monkey

3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2

BioCryst (BCRX) Upgraded to Buy: Here's Why

Zacks

3 months ago

BioCryst (BCRX) Upgraded to Buy: Here's Why

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

Zacks

4 months ago

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

MT Newswires

4 months ago

BioCryst Pharmaceuticals Enrolls First Patient in Phase 1 Trial of BCX17725 to Treat Netherton Syndrome

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

GlobeNewswire

4 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Secures Major US Health Department Influenza Drug Deal

TipRanks

4 months ago

BioCryst Secures Major US Health Department Influenza Drug Deal

BioCryst secures $69m contract from US to supply RAPIVAB for influenza

Pharmaceutical Technology

4 months ago

BioCryst secures $69m contract from US to supply RAPIVAB for influenza

With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns

Simply Wall St.

4 months ago

With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns

MT Newswires

4 months ago

BioCryst Awarded 5-Year US Influenza Contract Worth up to $69 Million

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

GlobeNewswire

4 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

MT Newswires

4 months ago

BioCryst Pharmaceuticals Completes Negotiations with Canadian Pricing Organization for Orladeyo

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

GlobeNewswire

4 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals

GuruFocus.com

4 months ago

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

GlobeNewswire

4 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

GlobeNewswire

4 months ago

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In August 2024

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In August 2024

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

5 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript

Motley Fool

5 months ago

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

Zacks

5 months ago

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

5 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

MT Newswires

5 months ago

BioCryst Pharmaceuticals Q2 Adjusted Loss Narrows, Revenue Rises

Associated Press Finance

5 months ago

BioCryst: Q2 Earnings Snapshot

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?

Zacks

6 months ago

Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

Zacks

6 months ago

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

BioCryst to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire

6 months ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

Zacks

6 months ago

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Zacks

6 months ago

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

BioCryst Pharmaceuticals' (NASDAQ:BCRX) growing losses don't faze investors as the stock spikes 18% this past week

Simply Wall St.

6 months ago

BioCryst Pharmaceuticals' (NASDAQ:BCRX) growing losses don't faze investors as the stock spikes 18% this past week

ORLADEYO gains approval in Peru for HAE prevention

Pharmaceutical Technology

6 months ago

ORLADEYO gains approval in Peru for HAE prevention

MT Newswires

6 months ago

BioCryst Pharmaceuticals Says Orladeyo Approved in Peru

ORLADEYO® (berotralstat) Approved in Peru

GlobeNewswire

6 months ago

ORLADEYO® (berotralstat) Approved in Peru

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings

Simply Wall St.

7 months ago

BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/14/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/13/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/12/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/11/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/10/2024

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

7 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

7 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

7 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

7 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

7 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

7 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

7 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

7 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

7 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

7 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

7 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

VanEck Semiconductor ETF Is Riskier Than You Think

Motley Fool

7 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Motley Fool

7 months ago

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Reuters

7 months ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Simply Wall St.

7 months ago

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

GuruFocus.com

7 months ago

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/07/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/06/2024

Most Shareholders Will Probably Agree With BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) CEO Compensation

Simply Wall St.

7 months ago

Most Shareholders Will Probably Agree With BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) CEO Compensation

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/05/2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 06/04/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 06/03/2024

MT Newswires

8 months ago

BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

GlobeNewswire

8 months ago

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 05/31/2024

Share on Social Networks: